secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106534
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Q2 loss narrows to $13.7M; China sale to AstraZeneca now ~$210M, cash runway into 2028
--------------------------------------------------------------------------------

- Net loss from continuing ops $13.7M ($3.38/sh) vs $47.1M loss ($11.79/sh) in Q2 2024; revenue $1.3M.
- Sale of FibroGen China to AstraZeneca now ~$210M total consideration (up $50M), including ~$125M net cash; close expected Q3 2025.
- Cash runway extended into 2028 upon China sale close; Q2 consolidated cash $142.1M.
- Agreed with FDA on pivotal Phase 3 design for roxadustat in LR-MDS with high transfusion burden; protocol filing Q4 2025.
- Phase 2 monotherapy trial of FG-3246 in mCRPC expected to start Q3 2025; combo data from UCSF study expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/0000950170-25-106534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/fgen-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer